Fabien Zoulim Selected Research

Antiviral Agents (Antivirals)

11/2022	Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue effective antiviral therapy.
6/2022	Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response.
6/2022	Assessing immunological and virological responses in the liver: Implications for the cure of chronic hepatitis B virus infection.
1/2022	Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis.
1/2022	Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.
1/2022	Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B.
8/2021	External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.
1/2021	Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study.
1/2021	Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort.
1/2021	Association of Metabolic Risk Factors With Risks of Cancer and All-Cause Mortality in Patients With Chronic Hepatitis B.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Fabien Zoulim Research Topics

Disease

125	Infections 06/2022 - 01/2002
106	Chronic Hepatitis B 11/2022 - 01/2002
49	Hepatitis B 11/2022 - 01/2002
48	Fibrosis (Cirrhosis) 06/2022 - 08/2005
29	Hepatocellular Carcinoma (Hepatoma) 06/2022 - 08/2005
22	Liver Diseases (Liver Disease) 01/2022 - 01/2002
19	Chronic Hepatitis C 06/2022 - 09/2004
12	Hepatitis C 01/2022 - 03/2003
12	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022 - 11/2004
12	Neoplasms (Cancer) 05/2021 - 06/2013
12	Hepatitis 01/2021 - 10/2004
10	Coinfection 01/2021 - 03/2014
10	Viremia 01/2018 - 02/2002
8	Disease Progression 01/2022 - 01/2002
8	Chronic Hepatitis (Chronic Active Hepatitis) 01/2022 - 03/2003
7	Virus Diseases (Viral Diseases) 01/2018 - 09/2003
6	Persistent Infection 01/2021 - 06/2004
5	Liver Neoplasms (Liver Cancer) 08/2021 - 10/2016
5	HIV Infections (HIV Infection) 01/2017 - 02/2006
4	Inflammation (Inflammations) 11/2022 - 10/2009
3	Hypertension (High Blood Pressure) 01/2021 - 01/2018
3	Carcinogenesis 12/2017 - 03/2016
2	Esophageal and Gastric Varices (Esophageal Varices) 06/2022 - 01/2019
2	Hypercholesterolemia 06/2022 - 07/2009
2	Portal Hypertension 01/2022 - 03/2011
2	Hemorrhage 01/2022 - 01/2021
2	Asthenia 10/2020 - 01/2013
2	Mitochondrial Diseases (Mitochondrial Disease) 03/2016 - 10/2014
2	Insulin Resistance 03/2016 - 10/2014
2	Diarrhea 04/2007 - 06/2002

Drug/Important Bio-Agent (IBA)

79	Antiviral Agents (Antivirals)IBA 11/2022 - 02/2002
40	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2022 - 08/2004
30	Hepatitis B e AntigensIBA 11/2022 - 06/2003
28	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 02/2002
26	InterferonsIBA 03/2022 - 01/2002
23	Ribavirin (Virazole)FDA LinkGeneric 10/2020 - 06/2002
19	NucleosidesIBA 12/2020 - 09/2002
18	Lamivudine (Epivir)FDA Link 01/2017 - 01/2002
17	AntigensIBA 11/2022 - 09/2007
16	Tenofovir (Viread)FDA Link 01/2022 - 07/2009
15	entecavir FDA Link 01/2022 - 05/2006
14	Pharmaceutical PreparationsIBA 01/2022 - 01/2002
13	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2006
12	Circular DNAIBA 01/2022 - 02/2002
12	VaccinesIBA 01/2021 - 01/2003
11	RNA (Ribonucleic Acid)IBA 11/2022 - 08/2005
11	Interferon-alpha (Interferon Alfa)IBA 01/2020 - 03/2003
9	NucleotidesIBA 10/2020 - 10/2004
9	Surface Antigens (Surface Antigen)IBA 01/2019 - 08/2004
9	adefovir dipivoxil (Hepsera)FDA Link 10/2010 - 06/2004
8	Alanine Transaminase (SGPT)IBA 01/2019 - 10/2004
7	Protease Inhibitors (Protease Inhibitor)IBA 04/2019 - 12/2011
7	adefovirIBA 03/2017 - 02/2002
7	telaprevirIBA 12/2015 - 11/2012
6	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2005
6	AntibodiesIBA 01/2021 - 01/2010
5	BilirubinIBA 06/2022 - 01/2018
5	Immunoglobulins (Immunoglobulin)IBA 05/2022 - 10/2006
5	Viral DNAIBA 01/2022 - 12/2007
5	CytokinesIBA 12/2019 - 01/2009
5	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 12/2015 - 11/2012
5	RacivirIBA 10/2013 - 09/2002
4	Netrin-1IBA 11/2022 - 03/2016
4	Peptides (Polypeptides)IBA 01/2022 - 01/2012
4	nasIBA 01/2020 - 07/2007
4	Biological ProductsIBA 04/2019 - 06/2012
4	SimeprevirIBA 04/2019 - 01/2015
4	LipidsIBA 03/2016 - 02/2009
4	Emtricitabine (Emtriva)FDA Link 04/2014 - 06/2003
3	hepatitis B hyperimmune globulinIBA 05/2022 - 10/2006
3	alpha-Fetoproteins (alpha-Fetoprotein)IBA 08/2021 - 01/2021
3	daclatasvirIBA 10/2020 - 11/2016
3	SofosbuvirIBA 10/2020 - 11/2016
3	EnzymesIBA 01/2019 - 01/2017
2	AlbuminsIBA 06/2022 - 01/2022
2	Coffee FDA Link 01/2022 - 01/2019
2	ChromatinIBA 01/2022 - 01/2017
2	Immunologic Factors (Immunomodulators)IBA 01/2021 - 09/2003
2	Hepatitis B Vaccines (Hepatitis B Vaccine)IBA 01/2021 - 09/2003
2	Membrane Proteins (Integral Membrane Proteins)IBA 01/2021 - 01/2009
2	Viral RNAIBA 01/2020 - 12/2015
2	pgRNAIBA 01/2020 - 01/2019
2	Transaminases (Aminotransferases)IBA 01/2019 - 01/2018
2	peginterferon alfa-2a (Pegasys)FDA Link 01/2017 - 01/2015
2	Messenger RNA (mRNA)IBA 10/2016 - 01/2011
2	LigandsIBA 03/2016 - 01/2011
2	EpitopesIBA 04/2015 - 11/2010
2	faldaprevirIBA 01/2013 - 12/2011
2	deleobuvirIBA 01/2013 - 12/2011
2	Adrenal Cortex Hormones (Corticosteroids)IBA 06/2012 - 08/2010
2	DNA VaccinesIBA 03/2012 - 01/2003
2	hepatitis B virus X proteinIBA 11/2011 - 07/2011
2	Glycoside Hydrolase InhibitorsIBA 04/2007 - 04/2006

Therapy/Procedure

103	Therapeutics 11/2022 - 01/2002
18	Liver Transplantation 05/2022 - 01/2002
5	Aftercare (After-Treatment) 06/2022 - 08/2010
3	Transplantation 01/2021 - 01/2018
2	Investigational Therapies (Experimental Therapy) 01/2020 - 11/2019
2	Retreatment 01/2020 - 01/2018
2	Duration of Therapy 01/2019 - 01/2015